A Stocks and Shares ISA is one of the most powerful wealth-building tools available to UK investors. Why? Because all dividends and capital gains are completely tax-free, no matter how large the pot grows.
That means if an investor manages to build a massive £500k ISA portfolio, all of it can be enjoyed without HMRC knocking at the door to take a slice. Therefore, having a large ISA at retirement can definitely go a long way to improve your lifestyle.
But for those who want to live a life of luxury, is £500k going to be enough?
Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.
The uncomfortable truth about a £500k ISA
The average UK retirement pot is around £137,800. So anyone who builds a £500k ISA is already doing 3.6 times better than the average Briton in terms of retirement savings while also being massively ahead of the average UK ISA investor.
It’s a genuinely impressive feat. And yet, sadly, it might not be enough. According to Pensions UK, a comfortable lifestyle in retirement requires an income of around £45,400 a year. Following the 4% withdrawal rule, a £500k ISA would only generate around £20,000 annually.
Luckily, the State Pension roughly adds another £12.5k on top of this. But that still falls short of the estimated benchmark needed for genuine comfort.
However, by continuing to make smart moves and picking the right companies to invest in, even a modest Stocks and Shares ISA can eventually grow into something far more substantial, surpassing £500k and even venturing into millionaire territory.
The only question is, which stocks should investors be looking at today?
The long-term compounder analysts love
Right now, one of the most high-conviction buys among institutional analysts in the UK market is AstraZeneca (LSE:AZN).
Twenty seven expert analysts are actively tracking the pharmaceutical giant, with 22 recommending the shares as either an outright Buy or an Outperform. And this bullish sentiment carries over into the share price forecasts as well.
The average share price target for AstraZeneca currently sits at 16,446p – around 28% higher than current levels. And looking at the latest results, it isn’t hard to understand why.
In the first quarter of 2026, total revenue grew 13% to $15.3bn, with oncology sales rising 16% and rare disease revenues climbing 15%. At the same time, core earnings per share reached $2.58, beating analyst estimates. And full-year guidance was once again reiterated in full, along with its $80bn revenue target by 2030.
Having said that, even a mature industry titan like AstraZeneca carries genuine investment risks. US drug pricing policy remains a live threat that could jeopardise future launches in other markets as well.
Meanwhile, a recent manufacturing scandal in China also required management to take a $0.3bn write-off, and its Chinese business is now facing even more regulatory headwinds.
But even if leadership is successful in overcoming these challenges, AstraZeneca shares nevertheless remain perpetually exposed to the risk of a clinical setback which can spark significant volatility – something investors will need to get comfortable with before allocating any capital.
The bottom line
Building a retirement pot that genuinely delivers £45,400 a year takes time and the right stocks. And in my opinion, AstraZeneca’s combination of consistent revenue growth and a world-class pipeline certainly makes it a business worth mulling.
Should you invest £5,000 in AstraZeneca Plc right now?
When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca Plc made the list?
Zaven Boyrazian does not hold any positions in the companies mentioned.
